Global Perspectives on Addiction Medicine/Addiction Physicians in Drug Abuse Epidemics (1.5 CME)
(1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:
to the World Drug Report of 2017, in 2015, ~250 million people used drugs, of
which around 29.5 million people- or 0.6% of the global adult population-were
engaged in problematic use and suffered from drug use disorders, including
dependence. Opioids accounted for 70% of the negative health impact
associated with drug use disorders worldwide. The current prescription opioid
epidemic in the US has resulted in serious morbidity and mortality of an
estimated 42,000 deaths in 2016 with a cost of $78.5 billion. This may be
partly due to a few unscrupulous physicians who have over-prescribed large
quantities of opioid pain medications, but the addiction medicine and
addiction physicians/psychiatrists still play an important role in
intervening with appropriate treatment and recovery programs for the patient
with substance use disorder. There is a great deal we can learn from the
nature of addiction and how it is addressed outside the United States. This
symposium will give attendees a perspective on work going on within ISAM, and
what it can teach us about addiction in our own national setting. The
symposium will be co-moderated by Dr. Kelly Clark, President of ASAM, and the
several speakers will present on many aspects of addiction medicine. Dr.
Gregory Bunt (US) will discuss “The Four Bio-Psycho-Social-Spiritual
Dimensions of Addiction: A Global Perspective”, Dr. Marc Galanter (US) will
discuss “12-step Model: Comparison in the US and Iran”, Dr. Kathline Brady
(US) will discuss “PTSD and substance use disorder”, and Dr. AlGhafri (Abu
Dhabi, UAE) will discuss the “Developments in Addiction Medicine in the
Middle East and Northern Africa”. This will be followed by a lively
|1.) The participants will learn about: (a) the current status on opioid epidemic.|
|2.) The participants will learn about: the current interventions used for patients with substance use disorders|
|3.) The participants will learn about the role addiction medicine and addiction physicians/psychiatrists could play in dealing with serious drug epidemics.|
Jag H. Khalsa
|Currently, Dr. Jag Khalsa serves as a Special Volunteer at the National Institute on Drug Abuse (NIDA), NIH, after retiring on October 31, 2017 from NIDA as the Chief of the Medical Consequences of Drug Abuse and Infections Branch, NIDA, NIH, DHHS. With 50+ years of experience in drug research, he was responsible for developing/administering a national and international program of clinical research on medical and health consequences of drug abuse and co-occurring infections (HIV, HCV, and others). Prior to joining NIDA in 1987, he served for ~10 yrs as a pharmacologist/toxicologist assessing safety (carcinogenic/teratogenic) potential of chemicals [INDs/NDAs] and food additives) and clinical evaluator at FDA. He has published in pharmacology, toxicology, epidemiology and medical journals. He serves on editorial boards of Journals of Addiction Medicine, Research on HIV/AIDS and Palliative Care, Frontiers of Neuroscience, and Clinical Infectious Diseases. He also served on numerous Federal and NIH level committees including the HHS Viral Hepatitis Implementation Group (VHIG), National Commission on Digestive Diseases and its two sub-committees (Liver Research, Diabetes Research), Federal Task Force on TB, NIH Steering Committee on Centers for AIDS Research, and Human Microbiome Workgroup. He has received distinguished service awards from the FDA Commissioner, NIDA and NIH Directors, Society of Neuro-Immune-Pharmacology (SNIP), Life Time Achievement Awards from SNIP and International Conference on Molecular Medicine (India) and MIT, India; a commendation from the US Congress, Awards of Merit from the International Society of Addiction Medicine (ISAM), the President of the American Society of Addiction Medicine (ASAM), and a Certificate of Appreciation from the Office of Assistant Secretary for Health (Drs. Howard Koh and Ron Valdiserri), DHHS. He has a Ph.D. in neuro-psycho-pharmacology, a Master’s degree in herbal pharmacology, post-doctoral training in CNS/Cardiovascular pharmacology at SK&F, and Toxicology at SRI International. E-mail: firstname.lastname@example.org; personal e-mail: email@example.com|
MD, FASAM, FISAM
Dr. Gregory Bunt graduated medical school in 1983 from NYU School of Medicine, and completed his residency in Psychiatry at the Albert Einstein College of Medicine in 1987. He was among the first to complete the Fellowship in Addiction Psychiatry at NYU School of Medicine (1989), and has since been on the NYU Medical School Faculty in the Division of Alcoholism and Drug Abuse, currently as an Assistant Clinical Professor of Psychiatry. He is a diplomat of the American Board of Psychiatry and Neurology with Special Added Qualifications in Addiction Psychiatry and a Fellow of the International Society of Addiction Medicine.Dr. Bunt is the Immediate Past President of the New York Society of Addiction Medicine and the Immediate Past President of the International Society of Addiction Medicine. He has been the Medical Director for Daytop Village and Daytop International for over 25 years. He has authored over a dozen publications, and speaks nationally and internationally about addiction medicine and therapeutic communities.
Marc Galanter, M.D., is a Professor of Psychiatry at NYU, Founding Director of the Division of Alcoholism and Drug Abuse, a Senior Editor of the Journal “Substance Abuse,” and co-editor of the American Psychiatric Association's “Textbook of Substance Abuse Treatment.” He has written four books, “Cults: Faith, Healing, and Coercion,” “Network Therapy for Alcohol and Drug Abuse,” “Spirituality and the Healthy Mind,” and "What is Alcoholics Anonymous?", and published over 200 peer-reviewed articles. His NIH and foundation-funded studies have addressed network therapy for substance abuse, pharmacologic treatment for addiction, the psychology of Twelve-Step recovery, and spirituality in healthcare.
Dr. Galanter attended Albert Einstein College of Medicine where he did his residency in psychiatry. After that he was a Clinical Associate of the National Institute of Mental Health, then an NIH Career Teacher. He later served as President of the Association for Medical Education and Research in Substance Abuse (AMERSA, 1976-1977), the American Academy of Addiction Psychiatry (AAAP, 1991-1992), and the American Society of Addiction Medicine (ASAM, 1999-2001). Among his awards are the Gold Achievement Award for Innovation in Clinical Care, the Oskar Pfister Award for Spirituality, Religion and Psychiatry, and the Seymour Vestermark Award for Psychiatric Education, all from the American Psychiatric Association; the McGovern Award for Medical teaching from AMERSA; the Smithers Award for Research form ASAM; and New York State's Award for Psychiatric Research.
MBBS, MPH, PhD
MBBS, MPH, PhD
|H.E. Dr Hamad Al Ghafri MBBS, MPH, PhD is the Director General and the Head of the WHO Collaborative Centre for substance use prevention and treatment of substance use disorders (National Rehabilitation Centre Abu Dhabi). He received his medical degree from the Faculty of Medicine, Jordan University of Science and Technology in 1999 and his Masters in Public Health from Tulane School of Public Health and Tropical Medicine, Tulane University, USA in 2002. He obtained his PhD from the Faculty of Medicine, University of Aberdeen, United Kingdom in 2013. He is the Head of Higher Committee for Treatment, Rehabilitation and Social Re-integration and a Board Member of Anti Dugs Council in the UAE. He is also a member of the Advisory Board of the College of Medicine, United Arab Emirates University. Internationally, he is the Vice President of the Arab Federation for Drug Prevention. He is a Mental Health Advisor to the Eastern Mediterranean Regional Office (EMRO) of the WHO and Chair of the Technical Advisory Group (TAG) of UNODC and WHO. He is a Board member of the International Society for Addiction Medicine and a Board Member of the International Consortium of Universities for Drug Demand Reduction (ICUDDR). He is also Emeritus Professor at the Faculty of Medicine, Jordan University of Science and Technology, Jordan. From 2016 to 2018 was the Chair of the Commissioners of the Global Centre for Credentialing and Education of Addiction Professionals (GCCC) of the Colombo Plan. His research interests include public health aspects and prevention of addiction, particularly in Arab countries. In recognition of his contribution to his field and the country, he was awarded the Sheik Rashed Award for Science and Culture in 2003 and 2014. In 2017, he was awarded the honor of Lifetime Membership of the American Society for Addiction Medicine.|
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of XX AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of XX LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of XX AMA PRA Category 1 Credit(s)™ for completing this course.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn XX Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.